These findings establish ZFPL1 as a key regulator of CRC progression through ASS1‐dependent urea cycle activation and immunomodulation, nominating the ZFPL1‐ASS1 axis as a therapeutic target, with Sal B demonstrating combinatorial potential with immunotherapy. This evidence concerns the gene ZFPL1 and colorectal carcinoma.